{"id":886016,"date":"2025-09-12T16:19:39","date_gmt":"2025-09-12T20:19:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/"},"modified":"2025-09-12T16:19:39","modified_gmt":"2025-09-12T20:19:39","slug":"vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/","title":{"rendered":"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Sept.  12, 2025  (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1&#215;1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.<\/p>\n<p align=\"justify\">Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1<br \/>Location: Virtual<\/p>\n<p align=\"justify\">A live webcast and archived replay of the fireside chat will be available on the Company\u2019s website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j4L5VvSYaZQxkTTPgcP7zv0mN6-U1a6N6jlHaFTMzM9oZ8r-ZjlRMZfPRAVN4Ds9V1QEGPE49OyvV4mvvVuPwdLgaJ1uHcq7wfE5wNNYn1bMmjYIeH_xq3MXKLKnwvM4-YTrV5AZ_PITcgD-OCEdzrXwHNSXXcztoYEB03rly1E=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.vorbio.com\/events-presentations\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Vor Bio<\/strong><br \/>\n        <br \/>Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GEDEpH0csa5ZJmD5xrq6sJ2fAV1KLPO9kYzuOaE74qly94wFdF1ZQvttaAgQ03qBh1CMMfTuee2xeCrU9RnuiA==\" rel=\"nofollow\" target=\"_blank\">www.vorbio.com<\/a>.<\/p>\n<p>\n        <strong>Media &amp; Investor Contacts:<\/strong><br \/>\n        <br \/>Carl\u00a0Mauch<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zsVz4KKg3tKooB1jOEOtoQdCGUM4E1Cw34Lx2xJqjHC4_y-6Ez1_v6c2h1wFcZ9145WezR4wUsKQElhzvenhXHFXbZckQ-hvHBgKjB6GGfQ=\" rel=\"nofollow\" target=\"_blank\">cmauch@vorbio.com<\/a><\/p>\n<p>Sarah Spencer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5HHs8G5m3mJBj8Dr_QkD4SzFwBTrNrxczYc0CGMEy3y-SNJXygQ0tTHKW_H1BLktDdACKEl098PmMvnsi1vOi8p6mDWqx0QoqPHMgCk2k5k=\" rel=\"nofollow\" target=\"_blank\">investors@vorbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjZkOWVmMGEtZmRjMi00M2ZiLTljODgtOTk0ZWYwMGI1NmNjLTEyMTM3MDUtMjAyNS0wOS0xMi1lbg==\/tiny\/Vor-Biopharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1&#215;1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Company\u2019s website at: https:\/\/ir.vorbio.com\/events-presentations\/ About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-886016","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1&#215;1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Company\u2019s website at: https:\/\/ir.vorbio.com\/events-presentations\/ About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven &hellip; Continue reading &quot;Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-12T20:19:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum\",\"datePublished\":\"2025-09-12T20:19:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/\"},\"wordCount\":154,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/\",\"name\":\"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=\",\"datePublished\":\"2025-09-12T20:19:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/","og_locale":"en_US","og_type":"article","og_title":"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1&#215;1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Company\u2019s website at: https:\/\/ir.vorbio.com\/events-presentations\/ About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven &hellip; Continue reading \"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-12T20:19:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum","datePublished":"2025-09-12T20:19:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/"},"wordCount":154,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/","name":"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=","datePublished":"2025-09-12T20:19:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODI0OSM3MTQ0NTUwIzIyMDIxNTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vor Bio to Participate in the Stifel\u00a02025 Virtual Immunology and Inflammation Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=886016"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886016\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=886016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=886016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=886016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}